Compare Digital Realty Trust, Inc. (DLR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Sana Biotechnology Inc — how do they compare? Digital Realty Trust, Inc. trades at $196.67 (market cap $70.61B), while Sana Biotechnology Inc trades at $3.81 (market cap $1.13B). The key difference: Digital Realty Trust, Inc. is far larger — about 62.5× Sana Biotechnology Inc's market cap, and Digital Realty Trust, Inc. pays a 2.56% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DLR | SANA | |
|---|---|---|
Market Cap | $70.61B | $1.13B |
Sector | Real Estate | Health |
52-Week High | $203.91 | $5.92 |
52-Week Low | $147.93 | $2.68 |
Enterprise Value | $89.32B | $1.05B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty (DLR) trades at $191.3, down 1.29% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates and raising full-year guidance, driven by record leasing and robust AI-driven data center demand. Revenue grew to $6.11B in 2025, with net income margin at 11.8%, though valuation ratios like P/E of 241.53 appear elevated. A dividend of $1.22 per share was declared for H1 2026.
DLR's outlook is positive due to strong AI infrastructure demand and raised guidance, but high valuation and significant capital expenditures pose risks. Analyst consensus is bullish with a $216.56 price target, though investors should monitor execution on growth targets and debt levels amid expanding investments.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
